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Abstract
IMPORTANCE—Sensorineural hearing loss (SNHL) is commonly caused by conditions that 
affect cochlear structures or the auditory nerve, and the genes identified as causing SNHL to date 
only explain a fraction of the overall genetic risk for this debilitating disorder. It is likely that other 
genes and mutations also cause SNHL.
OBJECTIVE—To identify a candidate gene that causes bilateral, symmetric, progressive SNHL 
in a large multigeneration family of Northern European descent.
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DESIGN, SETTING, AND PARTICIPANTS—In this prospective genotype and phenotype 
study performed from January 1, 2006, through April 1, 2016, a 6-generation family of Northern 
European descent with 19 individuals having reported early-onset hearing loss suggestive of an 
autosomal dominant inheritance were studied at a tertiary academic medical center. In addition, 
179 unrelated adult individuals with SNHL and 186 adult individuals reporting nondeafness were 
examined.
MAIN OUTCOMES AND MEASURES—Sensorineural hearing loss.
RESULTS—Nine family members (5 women [55.6%]) provided clinical audiometric and medical 
records that documented hearing loss. The hearing loss is characterized as bilateral, symmetric, 
progressive SNHL that reached severe to profound loss in childhood. Audiometric configurations 
demonstrated a characteristic dip at 1000 to 2000 Hz. All affected family members wear hearing 
aids or have undergone cochlear implantation. Exome sequencing and linkage and association 
analyses identified a fully penetrant sequence variant (rs35725509) on chromosome 12q21 
(logarithm of odds, 3.3) in the TMTC2 gene region that segregates with SNHL in this family. This 
gene explains the SNHL occurrence in this family. The variant is also associated with SNHL in a 
cohort of 363 unrelated individuals (179 patients with confirmed SNHL and 184 controls, P = 7 × 
10−4).
CONCLUSIONS AND RELEVANCE—A previously uncharacterized gene, TMTC2, has been 
identified as a candidate for causing progressive SNHL in humans. This finding identifies a novel 
locus that causes autosomal dominant SNHL and therefore a more detailed understanding of the 
genetic basis of SNHL. Because TMTC2 has not been previously reported to regulate auditory 
function, the discovery reveals a potentially new, uncharacterized mechanism of hearing loss.
Hearing loss is one of the most common sensory defects in humans, affecting approximately 
1 in 1000 newborns, with an estimated 50% having genetic causes.1,2 Incidence of hearing 
loss is estimated as 0.5% in older children (aged 3-17 years)3 and 17% in adults.4 
Sensorineural hearing loss (SNHL) is caused by conditions that affect the cochlear structures 
or the auditory nerve. In addition to genetic factors, environmental insults contribute to the 
development of SNHL.5-8 A large number of genetic loci have been identified that 
contribute to autosomal dominant, autosomal recessive, X-linked, Y-linked, and 
mitochondrial forms of nonsyndromic SNHL.9 Fifty-three independent genetic loci 
contributing to nonsyndromic autosomal dominant SNHL have been discovered, with 142 
mutations in 31 genes identified. Similarly, more than 76 loci contribute to recessive forms 
of SNHL. However, those identified to date only explain a fraction of the overall genetic risk 
for SNHL, and more remain to be discovered.
Recommendations and outcomes of SNHL habilitation, such as hearing aids and cochlear 
implants, depend on myriad factors, and advances in genetic testing can provide useful 
etiologic information to aid clinical decisions. Initiatives to incorporate genetic testing in 
early hearing detection and intervention programs aim to inform the cause of congenital 
hearing loss in newborns and the risk of late-onset hearing loss in children.10,11 Although 
clinical testing is expanding to identify mutations, much is still unknown about the genetic 
causes and molecular mechanisms of progressive SNHL, and the effect of genetic testing on 
clinical management of SNHL remains limited.
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The objective of this study was to identify a candidate gene causing bilateral, symmetric, 
progressive SNHL in a multigeneration family of Northern European descent. Our analyses 
identified a sequence variant in a previously uncharacterized gene, TMTC2 (OMIM 
615856), that is strongly associated with SNHL in this family. The gene variant is also 
associated with SNHL in a group of unrelated individuals, suggesting that TMTC2 may be 
of broader importance for normal auditory function.
Methods
Study Participants
Family members were recruited in Wisconsin and adjacent Midwestern US states from 
January 1, 2006, through April 1, 2016. All were of Northern European descent. Hearing 
loss status was reported by family members (for deceased and very young individuals), self-
reported, or clinically assessed by standard audiometric testing. All available audiograms 
were used to calculate age-related typical audiograms, as described by Topsakal and 
colleagues.12 Octave-frequency threshold values of the right ear were plotted by age and 
frequency-specific linear regression equations used to calculate threshold values for each 
decade of age from 0 to 70 years, which were then transposed to generate age-related typical 
audiograms.
In addition, unrelated adult volunteers of Northern European descent with confirmed SNHL 
requiring a cochlear implant or hearing aids were included who were patients of, or referrals 
to, our clinical program. A control group of adults of Northern European descent from the 
Midwestern US states who self-reported as not having deafness was also included.
All procedures were approved by the Children’s Hospital of Wisconsin Institutional Review 
Board. Written informed consent was obtained from all study participants for this study and 
for publication. Data were deidentified for genetic analyses but not for phenotypic analyses.
DNA Sample Collection
DNA was obtained from saliva, buccal swabs, or blood using Oragene Collection Kits and 
Oragene prepIT-LP2 reagent (DNA Genotek) for saliva, Isohelix T-Swabs (Boca Scientific) 
and PUREGENE DNA Isolation Kit (Gentra Systems) for buccal swabs, and the whole-
blood PUREGENE DNA Isolation Kit (Gentra Systems) for blood. Extracted DNA was 
resuspended in Tris-EDTA buffer and stored at −20°C.
Linkage Analysis
DNA samples were genotyped using the Human SNP Array 6.0 (Affymetrix). Data were 
analyzed using the Genotyping Console software suite (Affymetrix) with default parameters. 
Any genotype that was inconsistent with mendelian segregation was blanked using 
SimWalk2.13
A subset of markers was selected for linkage analysis to minimize the linkage disequilibrium 
(LD) between adjacent variants. Only single-nucleotide polymorphisms (SNPs) with a 
minimal distance between markers of 25 000 bp and a minimum minor allele frequency of 
0.25 were included. Two-point linkage analysis using 61 108 SNP markers was conducted in 
Runge et al. Page 3
JAMA Otolaryngol Head Neck Surg. Author manuscript; available in PMC 2017 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Sequential Oligogenic Linkage Analysis Routines (SOLAR)14 using a probit liability model 
with ascertainment correction.15
Resequencing
Six family members were analyzed by exome sequencing using the Agilent SureSelectXT 
All Exon V5 Target Enrichment System (affected individuals III:7, IV:6, IV:9, V:7, and V:11 
and unaffected individual III:8). All samples were pair-end sequenced (Illumina GAII). 
Fastq files generated from CASAVA, version 1.8 were aligned with the human reference 
sequence GRCh37 using standard protocols (details available on request). Sequence variants 
were called with FreeBayes, version 0.8.9 (http://arxiv.org/abs/1207.3907).
Association Analysis
Association analyses were conducted in SOLAR14 in the linkage cohort using SNP Array 
6.0 genotype data. When necessary, proxy SNPs were selected using the SNP Annotation 
and Proxy Search (https://www.broadinstitute.org/mpg/snap/).
Genotype dosage scores were coded as 0, 1, or 2 copies of the SNP minor allele. Estimates 
of heritability were performed using a probit liability model with ascertainment correction.15 
Neither age nor sex was a significant correlate of hearing loss, and neither was included as a 
covariate in the analysis. Initially, each genotype dosage score was applied as a covariate to 
the liability model for hearing loss, and the likelihood of this model was compared with that 
of the null model of no association. The likelihood ratio test statistic is distributed as a 
statistic. Bayesian model selection14 was used to choose the most parsimonious model 
(details in the Results section) and minimize LD effects. The identified sequence variant was 
genotyped in additional members of the family and unrelated samples, using Invader 
technology.16,17
Results
Nine family members (5 women [55.6%]) provided audiometric and medical records that 
documented hearing loss. The group of unrelated adult volunteers with confirmed SNHL 
included 179 individuals, with 146 requiring a cochlear implant and 33 requiring hearing 
aids (mean [SD] age, 82 [18] years; age range, 18-94 years; 94 women [52.5%]). The 
control group who self-reported as not having deafness included 186 adults (mean [SD] age, 
64 [8] years; age range, 50-83 years; 125 women [67.2%]).
We initially analyzed a large multigeneration family of Northern European descent with a 
likely autosomal dominant form of bilateral, symmetric, progressive SNHL reaching severe 
to profound loss of hearing in childhood (Figure 1). Figure 2A and B show examples of the 
audiometric configuration and progression of hearing loss with age for family members III:7 
and V:7 (right ear only). Figure 2C shows examples of available audiometric data for 3 of 
the unrelated individuals with SNHL of various ages who were ultimately found to have the 
same genetic mutation as the Wisconsin family (right ear only). Age-related typical 
audiograms from the Wisconsin family demonstrated progressive, high-frequency sloping 
hearing loss with a characteristic dip at 1000 to 2000 Hz and peak at 4000 Hz (Figure 2D).
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The exact ages at hearing loss onset were not determinable; however, the earliest available 
audiograms and medical records were analyzed for the 9 individuals who provided them 
(Table). Clinical record data confirmed childhood-onset hearing loss for 6 family members. 
For the remaining 3 individuals, childhood onset was self-reported. All affected individuals 
are auditory-oral communicators who wear hearing aids, and 2 family members have 
received unilateral cochlear implants (individuals III:7 and V:11). The 2 individuals with 
implants have had benefit from this intervention consistent with postlingual onset of severe 
to profound hearing loss.
To identify the gene causing the SNHL in this family, 20 individuals across 4 generations, 
including 11 affected individuals, were analyzed. Complete genotype data for all individuals 
were obtained on 631 644 variants. Two-point linkage analysis identified a region on 
chromosome 12q21 (logarithm of odds [LOD], 3.3) (Figure 3). The 1 – LOD CI spans 13 
Mb (79-92 Mb, GRCh37/hg19) and contains 48 known genes. Three individual SNPs were 
strongly linked to SNHL (LOD, >3), and 53 additional SNPs had suggestive evidence of 
linkage (LOD, >2). None of the genes in this region has been implicated in autosomal 
dominant hereditary hearing loss,9 and the linkage region does not overlap with any other 
SNHL loci. However, the region contains 2 genes, PTPRQ (OMIM 603317) and OTOGL 
(OMIM 614925), that have been identified at the DFNB84 locus, causing an autosomal 
recessive form of SNHL.
As shown in Figure 3, the linkage analysis also uncovered a second region on chromosome 
5q11.2-14.3 with suggestive evidence of linkage (LOD, 2.8). However, no evidence for 
linkage remains when the analysis is performed conditional on the locus on chromosome 
12q (LOD, 0.18), suggesting that the locus on 12q21 harbors the causal gene for SNHL in 
this family.
To identify the likely causal gene in the linkage interval and to simultaneously explore the 
role of other previously reported loci for autosomal dominant hearing loss, we selected 6 
individuals (III:7, III:8, IV:6, IV:9, V:7, and V:11) from the family for resequencing using 
exome capture. The sequence analysis revealed 84 357 SNP variants across the genome. 
Because the resequencing included 1 unaffected founder (individual III:8) and 5 affected 
individuals, we postulated that the unaffected individual III:8 had to be homozygous for the 
reference allele, and 4 of 5 affected individuals (III:7, IV:9, V:7, and V:11) had to be 
heterozygous because 1 parent was unaffected. Individual IV:6 had 1 confirmed affected 
parent (III:5), and the phenotype of the other (deceased) parent was undetermined, so this 
individual could be heterozygous or potentially homozygous for the minor associated allele. 
Across the linkage interval on chromosome 12, we found that 4 nonsynonymous and 1 
untranslated region variant matched this genotype expectation. All of these variants were 
previously identified in the 1000 Genomes Project (http://www.1000genomes.org/, phase 1 
call set, February 2012). We tested these 5 variants for association with SNHL in a stepwise 
regression model selection procedure in SOLAR18 using proxy variants selected from the 
Affymetrix SNP chip panel when needed (SNP Annotation and Proxy Search, http://
www.broadinstitute.org/mpg/snap/) for all 20 individuals included in the initial linkage 
analysis. We used a bayesian model selection procedure14 to identify the minimal number of 
variants likely to contribute to variation in the trait. The most parsimonious association 
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model contained only 1 variant, rs35725509, in exon 3 of the TMTC2 gene (P = 2.28 × 10−6, 
N = 20). This model had a posterior probability of 1 for the association with the single 
variant; no other variant tested had a posterior probability of association exceeding 0.42 (and 
the other variants were not in substantial LD with rs35725509).
We did not uncover any putative functional (nonsynonymous) sequence variants in the genes 
PTPRQ and OTOGL, the 2 genes in the linkage interval previously implicated in an 
autosomal recessive form of SNHL (the DFNB84 locus) that matched the expected genotype 
distribution for the sequenced individuals. The 2 genes are more than 2 Mb away from the 
rs35725509 variant in TMTC2, making it unlikely that long-range LD between the variant in 
TMTC2 and a causal variant in either of these 2 genes led to the result we obtained in our 
association analysis.
To validate the association of the variant rs35725509 with SNHL in the family, we 
genotyped 47 individuals from the family (all 32 individuals highlighted in Figure 1 and an 
additional 15 unaffected descendants of individual III:5 and found a total of 13 affected 
individuals) and 40 control Centre d’Etude du Polymorphisme Humain DNA samples. All 
unaffected family members and Centre d’Etude du Polymorphisme Humain DNA samples 
were homozygous for the wild-type G allele, and 11 of 12 affected individuals were 
heterozygous. One affected individual (individual IV:7) was homozygous for the alternate A 
allele. Although homozygous, the hearing loss phenotype for individual IV:7 was not more 
severe compared with other family members (Table). The genotypes for all 6 individuals 
who underwent sequencing (III:7, III:8, IV:6, IV:9, V:7, and V:11) were confirmed, and no 
discrepancies were uncovered between the sequencing and genotyping data. The variant 
revealed a strong association with SNHL (P = 6 × 10−13, N = 47) in the extended family, and 
no residual heritability remained when the variant was included in the association model, 
suggesting that this gene region is responsible for a fully penetrant form of autosomal 
dominant SNHL in this family.
Because the identified variant in TMTC2, rs35725509, has been detected in the 1000 
Genomes and Exome Sequencing (http://evs.gs.washington.edu/EVS/) European call sets 
(1% and 0.8% frequency, respectively), it is possible that the variant may be associated with 
SNHL in other patients beyond the initial family. This finding is further supported by the 
family data because individual IV:7 is homozygous for the mutation, suggesting that her 
father, who married into the family, was a carrier for the mutation as well (no DNA or 
phenotypic information was available from this deceased individual). DNA analysis from the 
179 unrelated volunteers with confirmed SNHL revealed an allele frequency for the minor A 
allele of 0.031, with 11 individuals being heterozygous for the sequence variant. In contrast, 
of the 186 patients of Northern European descent from the Midwestern United States who 
self-reported not having deafness, 184 were homozygous for the G allele of rs35725509 (P = 
7 × 10−4). Two individuals had the minor A allele; however, on follow-up to confirm hearing 
status, 1 individual (currently deceased) was reported by family members to have worn 
hearing aids, and the other individual was unable to be contacted. The combined data 
confirm that the variant rs35725509 is strongly associated with SNHL in both the original 
family and the general population; therefore, TMTC2 likely represents a novel gene 
affecting hearing in humans.
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Analysis of an expressed sequence tag profiling human gene expression database (http://
www.ncbi.nlm.nih.gov/unigene/) revealed expression of TMTC2 in 21 of 45 tissues 
examined, including adipose tissue, kidney, heart, and intestine; however, no expressed 
sequence tags of TMTC2 were detected in ear tissue. Likewise, the Mouse Genome 
Informatics website (http://www.informatics.jax.org/) reports expression of TMTC2 in 40 
different tissues but not in ear or cochlear tissue. We collected cochlear tissue samples from 
3 human cadavers, and reverse transcription–polymerase chain reaction analysis confirmed 
robust expression of TMTC2 in these samples when compared with expression of HPRT 
(OMIM 308000), a gene known to be expressed in the inner ear of humans,19 further 
validating the gene as a potential regulator of normal hearing function (Figure 4).
Discussion
Our analysis of a large family with SNHL revealed a previously uncharacterized gene that is 
likely to affect normal hearing and inner ear function. Interestingly, the identified variant in 
TMTC2, rs35725509, is strongly associated with SNHL not only in the original family but 
also in the general population, suggesting that the gene plays an important role in regulating 
and maintaining auditory function in humans. The specific function of TMTC2 is unknown, 
but TMTC2 is a transmembrane protein that contains 10 tetratricopeptide repeat motifs 
(http://www.uniprot.org/uniprot/Q8N394) and a structural motif that consists of 34 
degenerate amino acids. The motif is found in a number of proteins and mediates protein-
protein interaction (http://www.uniprot.org/keywords/KW-0802). A previous study20 
localized TMTC2 to the endoplasmic reticulum in HEK293 cells and found it to be 
associated with the endoplasmic reticulum calcium uptake pump SERCA2B, but the detailed 
function of the protein and its putative role in other tissues have not been elucidated. It is 
possible that TMTC2 is involved in a novel mechanism that affects hearing in humans.
The variant rs35725509 in TMTC2 may not actually be causing the observed hearing loss in 
the family because the mutation is found in a relatively high percentage of individuals of 
Northern European descent in the 1000 Genomes and Exome Sequencing (http://
evs.gs.washington.edu/EVS/) European call sets (1% and 0.8%, respectively). The TMTC2 
gene spans a genomic interval of 447 kb on human chromosome 12. The exome capture did 
not cover the 5′ and 3′ untranslated regions or any of the putative regulatory upstream or 
intronic sequences of TMTC2. The sequence variant rs35725509 is located in an LD block 
that spans 28 kb around exon 3 and has long-range LD with other SNPs in adjacent regions 
of TMTC2, suggesting that the mutation (or mutations) causing SNHL in this family may be 
located in other regions of the gene. However, there is no evidence that the LD extends 
beyond the TMTC2 gene region, and any causal variant would be located in this gene. 
Future studies and sequencing analyses are needed to identify the true causal sequence 
variant (or multiple variants) in the family and other patients with SNHL to fully assess the 
role of TMTC2 mutations in SNHL in the general population. Additional functional studies 
will need to elucidate the role of TMTC2 in normal auditory function to determine whether 
this novel gene may provide clues for alternative novel treatment approaches in the future.
To date, 53 loci and 31 genes have been identified in which mutations cause nonsyndromic 
autosomal dominant SNHL (http://hereditaryhearingloss.org). Only 2 of all the 
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nonsynonymous mutations reported for these genes (Val306Met and Gly662Glu in MYO1A 
[OMIM 601478]) are found at frequencies comparable to rs35725509 in TMTC2 in the 
general population, as assessed from the National Heart, Lung, and Blood Institute Exome 
Resequencing data (1.0% and 3.8%, respectively); all others are extremely rare and often 
specific to a single family. The audiometric configuration and progression patterns in this 
family are similar to phenotypes described for DFNA2 (OMIM 603537), particularly for 
KCNQ4 (OMIM 603537) pore-region mutations W276S in Dutch and Japanese 
families12,21,22 and G285C in a US family.23,24 We did not identify any nonsynonymous 
variants that matched the expected genotypes for the included individuals in any of the other 
previously reported genes and loci causing autosomal dominant SNHL, including KCNQ4 at 
the DNFA2 locus, suggesting that a mutation in the gene TMTC2 is likely responsible for 
the observed hearing loss. This finding, again, suggests that this novel mutation may be an 
important contributor to autosomal dominant SNHL.
Conclusions
A previously uncharacterized gene, TMTC2, was identified as a candidate for causing 
progressive SNHL in humans. This finding provides a more detailed understanding of the 
genetic basis of SNHL and reveals a potentially new, uncharacterized mechanism of hearing 
loss. Ultimately, these results contribute to improving our diagnostic capabilities and reveal 
targets for more effective treatment strategies for SNHL.
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Key Points
Question
What is the genetic cause of progressive sensorineural hearing loss (SNHL) in a large 
multigeneration family?
Findings
Exome sequencing and linkage and association analyses identified a fully penetrant 
sequence variant (rs35725509) on chromosome 12q21 (logarithm of odds, 3.3) in the 
TMTC2 gene region that segregates with SNHL in the family. The variant is also 
associated with SNHL in a cohort of unrelated individuals.
Meaning
A previously uncharacterized gene, TMTC2, was identified as causing progressive SNHL 
in humans. This finding identifies a novel locus and reveals a potentially new, 
uncharacterized mechanism of hearing loss.
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Figure 1. Pedigree of a Family With Sensorineural Hearing Loss
Hearing loss status was self-reported, reported by family members (for deceased and very 
young individuals), or based on records of audiometric tests. Individuals who provided 
audiometric records were III:7, IV:5, IV:6, IV:7, IV:9, IV:10, IV:13, V:7, and V:11. Hearing 
loss was self-reported for III:5, IV:3, IV:8 (before death), V:3, and V:5. Family members 
reported hearing loss for II:2, II:3, III:2, III:3, and VI:1. Deceased individuals with unknown 
hearing loss cause are indicated by gray symbols; all affected individuals are represented by 
filled symbols.
a
 Individuals included in the initial linkage analysis.
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Figure 2. Hearing Loss Phenotype
A and B, Serial audiograms showing progressive hearing loss from the right ear of 2 family 
members representing different generations. C, Audiograms from 3 unrelated individuals 
with sensorineural hearing loss (SNHL) who harbor the same mutation found in the 
Wisconsin family. D, Age-related typical audiograms calculated from right-ear audiograms 
of affected family members. db HL indicates decibels Hearing Level.
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Figure 3. Genome-Wide Linkage Plot
The logarithm of odds (LOD) score from a 2-point linkage analysis of all 631 644 single-
nucleotide polymorphisms in 20 individuals of the sensorineural hearing loss family are 
shown relative to the chromosomal location of each variant.
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Figure 4. Reverse Transcription–Polymerase Chain Reaction Gene Expression Analysis From 
Human Inner Ear Tissue
Cycle threshold (Ct) values for TMTC2 are shown in dark blue, and Ct values for a 
reference gene, HPRT, are shown in light blue. Higher Ct values indicate lower gene 
expression levels. No target and no reverse transcription controls had no signal after 50 
cycles. Error bars indicate SE.
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Table
Characterization of the Earliest Audiometric Data Available for the 9 Family Members 
Who Provided Recordsa
Pedigree
Age of Earliest
Audiogram, y 3-PTA, dB Degree of Hearing Loss Comments
III:7 20 60 Mild to profound Age, 20 years; medical record reported
“deafness, partial, bilateral-since
childhood“
IV:5 44 68 Moderate to severe NA
IV:6 39 75 Moderate to severe NA
IV:7 53 67 Mild to profound NA
IV:9 11 85 Severe to profound NA
IV:10 36 95 Profound Age, 40 years; medical record reported
“bilateral hearing problems as a child”
IV:13 16 87 Severe to profound NA
V:7 2 30 Mild SRT of 20 dB HL; SF testing
V:11 2 70 Moderate to profound SF testing
Abbreviations: 3-PTA, 3-frequency pure tone average; db HL, decibels Hearing Level; NA, not available; SF, sound field; SRT, speech recognition 
threshold.
a
The 3-PTA hearing thresholds were measured at frequencies of 0.5, 1, and 2 kHz. The SF testing was performed via speakers and only reflects 
thresholds of the better ear; however, given the symmetry of thresholds between ears at later evaluations, it was assumed the hearing losses were 
symmetrical.
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